The medical technology company Synthetic MR states that the integration of Combinostics, which was acquired at the beginning of 2025, has broadened the company's product portfolio and strengthened its position in imaging diagnostics of neurodegenerative diseases. This is stated in a press release. cNeuro cMRI has been integrated into the offering together with SyMRI and, after the acquisition, has received regulatory approval in Europe for updates that include automated detection of ARIA in the treatment of Alzheimer's disease. In parallel, cNeuro cMRI has been launched in India, where the company is building on the established presence of SyMRI.